Since 2026, a total of 17 biomedical companies have been listed on the Hong Kong Stock Exchange, accounting for 16.19% of the total number of current IPOs, raising a total of HK$18.501 billion. Meanwhile, 110 biomedical companies have submitted listings to the Hong Kong Stock Exchange during the year, covering popular tracks such as oncology, CGT, nuclear drugs, ophthalmic drugs, and medical devices. Two major trends are particularly obvious in this round of listing boom: one is that many A-share pharmaceutical companies are running into the market and are scrambling to build an “A+H” dual capital platform; the second is that many companies have repeatedly submitted statements, even “breaking through the Hong Kong Stock Exchange”, with a high percentage of repeated declarations.

Since 2026, a total of 17 biomedical companies have been listed on the Hong Kong Stock Exchange, accounting for 16.19% of the total number of current IPOs, raising a total of HK$18.501 billion. Meanwhile, 110 biomedical companies have submitted listings to the Hong Kong Stock Exchange during the year, covering popular tracks such as oncology, CGT, nuclear drugs, ophthalmic drugs, and medical devices. Two major trends are particularly obvious in this round of listing boom: one is that many A-share pharmaceutical companies are running into the market and are scrambling to build an “A+H” dual capital platform; the second is that many companies have repeatedly submitted statements, even “breaking through the Hong Kong Stock Exchange”, with a high percentage of repeated declarations.